| Excerpt | Reference |
|---|
| "Ewing's tumor is showing increased survival rates from radiation therapy alone, as well as by use of systemic adjuvant chemotherapy combined with local radiation." | ( Copeland, MM, 1977) |
| "Ewing's tumor is usually characterized by its content of glycogen, neuroblastoma by its absence." | ( Ross, WE; Triche, TJ, 1978) |
| "Eight cases of Ewing's tumor are reported." | ( Claver, M; Fernández, P; García Miguel, P; González, MC; Hurtado, T; Nuñoz Villa, A; Petrement, C, 1976) |
| "Extraosseous Ewing's sarcoma is a primitive small round cell neoplasm found in children and young adults." | ( Khiew, KF; Kuo, SH; Tay, CH, 1992) |
| "Because Ewing's sarcoma is usually sensitive to chemotherapy, initial chemotherapy, in neurologically stable patients, could be attempted first without surgical resection." | ( el-Khoury, GY; Haddad, FS; Haddad, SF; Hitchon, PW; Sharafuddin, MJ, 1992) |
| "Extraskeletal Ewing's sarcoma is rarely found arising in the head and neck region." | ( Ironside, JW; Lane, S, 1990) |
| "The histogenesis of Ewing sarcoma is still controversial; we therefore studied the expression of intermediate filaments (IF) in cell lines derived from Ewing tumors since identification of IF in tumor cells is considered a reliable marker of tissue origin and differentiation." | ( Brouet, JC; Dellagi, K; Lenoir, GM; Lipinski, M; Paulin, D; Portier, MM, 1987) |
| "Prognosis in Ewing's sarcoma is inversely related to the extent of the disease at the time of presentation." | ( Jones, GR; Laug, WE; Miller, JH; Shore, NA; White, L, 1987) |
| "Ewing's sarcoma is a rare, but highly malignant bone tumor." | ( Matejovsky, Z; Povysil, C, 1986) |
| "Thus Ewing's sarcomas are relatively rich in beta-adrenergic sites, and several tumors appear to have a coupling lesion involving guanine nucleotide-dependent regulatory protein interaction with beta-adrenergic receptors and adenylate cyclase, similar in phenotype to that described in the (unc) variant of S49 mouse lymphoma." | ( Burdsall, J; Hollinger, B; Neely, J; Whitsett, JA; Workman, L, 1983) |
| "Neuroblastoma and Ewing's sarcoma are examples of pediatric cancers in which disseminated disease is often present at diagnosis or develops later in spite of combination therapy." | ( Coccia, P; Graham-Pole, J; Gross, S; Herzig, RH; Lazarus, HM; Strandjord, S; Weiner, R, 1984) |
| "Ewing's sarcoma is an uncommon malignancy that usually occurs in childhood and is rare in the mandible." | ( Berk, R; Heller, A; Heller, D; Klein, EA; Schwartz, S, 1995) |
| "Ewing's sarcoma is treated by multiple agent chemotherapy." | ( Tomita, K; Tsubota, S; Tsuchiya, H, 1993) |
| "Ewing's sarcoma is a bone tumor that rarely arises in the head and neck region." | ( Daniels, HA; Howard, DJ, 1993) |
| "Ewing's sarcoma is a primary bone neoplasm that rarely occurs in the hand." | ( Cook, MA; Manfredi, OL, 1996) |
| "As most failures in Ewing's sarcoma are systemic, improved EFS requires more effective systemic chemotherapy." | ( Donaldson, SS; Gilula, L; Glicksman, A; Laurie, F; Link, MP; Manning, J; Neff, J; Reinus, W; Shuster, JJ; Thompson, E; Torrey, M, 1998) |
| "Extraskeletal Ewing's sarcoma is rare, and very few data are available addressing optimal surgical and oncologic treatment modalities." | ( Ahmad, R; Davis, M; Mayol, BR; Rougraff, BT, 1999) |
| "The prognosis of Ewing's sarcoma is improving with radiotherapy and chemotherapy." | ( Bhatoe, HS; Deshpande, GU, 1998) |
| "Extraskeletal Ewing's sarcoma is a rare tumor." | ( Iijima, S; Ishida, K; Maesawa, C; Masuda, T; Saito, K; Sato, N; Suzuki, M; Tamura, G; Tarusawa, M; Yoshinori, N, 2002) |
| "Ewing's sarcoma is rarely located at the base of the skull." | ( Dehesdin, D; Fréger, P; Laquerrière, A; Proust, F; Velche-Haag, B, 2002) |
| "Ewing sarcoma is the second most common bone tumor in childhood." | ( Delattre, O; Poupon, MF; Sancéau, J; Sastre-Garau, X; Wietzerbin, J, 2002) |
| "The Ewing sarcoma is the second most common bone tumor in children and young adults." | ( Besançon, F; Djavaheri-Mergny, M; Wietzerbin, J, 2003) |
| "Ewing sarcoma is a relatively uncommon malignant bone neoplasm that usually occurs in children and young adults and involves the major long bones, pelvis, and ribs." | ( Alper, F; Eroğlu, A; Gündoğdu, C; Karaoğlanoğlu, N; Kürkçüoğlu, IC, 2004) |
| "Ewing sarcoma is a rapidly growing mesenchymal tumor in young adults." | ( Hansen, Tv; Koefoed, P; Nielsen, FC; Rauch, D; Rehfeld, JF; Reubi, JC; Stauffer, E, 2004) |
| "Cervical spinal Ewing's sarcomas are rare and cause problems in diagnosis." | ( Kara, G, 2004) |
| "Ewing sarcoma is the second most common bone tumor in childhood." | ( Sancéau, J; Wietzerbin, J, 2004) |
| "Ewing sarcoma is a highly malignant tumor of bone preferentially arising in children and young adults." | ( Araujo, ES; Bacchini, P; Bertoni, F; Do, I; Kalil, RK; Park, YK; Unni, KK, 2007) |
| "Ewing's sarcoma is a common malignancy of bone and soft tissue that occurs most often in children and young adults." | ( Bernard, PS; Coffin, CM; Lewis, TB, 2007) |
| "Ewing's sarcoma is a relatively rare osseous malignant tumour." | ( Bellakhdar, F; Gana, R; Laghmari, M; Lakhdar, F; Maaqili, R; Moufid, F, 2008) |
| "Extraskeletal Ewing's sarcoma is rarely found in the head and neck regions." | ( Cho, JH; Cho, SI; Ko, JS; Park, YH; Ryoo, BY; Yang, SH; Youn, SM, 2007) |
| "Ewing's sarcoma is a highly malignant neoplasm of bones which accounts for the 10% of primary bone malignancies." | ( Alexiou, GA; Antypas, C; Balafouta, ME; Moschovi, M; Prodromou, N; Sfakianos, G; Tourkantoni, N; Tsiotra, M, 2011) |
| "Cutaneous Ewing's sarcoma is currently treated in the same way as osseous Ewing's sarcoma (wide surgical excision, adjuvant radiotherapy when surgical margins are unsatisfactory, systemic adjuvant chemotherapy, and, in some cases, bone marrow transplant)." | ( Delaplace, M; Goré, C; Machet, L; Mélard, P; Perrinaud, A; Vergier, B, 2011) |
| "Ewing's sarcoma is a pediatric cancer of the bone that is characterized by the expression of the chimeric transcription factor EWS-FLI1 that confers a highly malignant phenotype and results from the chromosomal translocation t(11;22)(q24;q12)." | ( Bennett, KL; Colinge, J; Kontny, U; Kovar, H; Kubicek, S; Lissat, A; Müllner, MK; Nijman, SM; Rix, U; Stukalov, A; Superti-Furga, G; Winter, GE, 2011) |
| "Ewing's sarcoma is the second most frequent primary malignant bone tumor, mainly affecting children and young adults." | ( Guo, W; Lu, XC; Ren, TT; Tang, GQ; Zhang, S; Zhao, FL, 2012) |
| "Ewing sarcoma is one of the most frequent bone cancers in adolescence." | ( Buttarelli, M; Di Conza, G; Mancini, F; Monti, O; Moretti, F; Pellegrino, M; Pontecorvi, A; Scotlandi, K, 2012) |
| "Ewing sarcoma is an aggressive pediatric cancer of the bone and soft tissue, in which patients whose tumors have a poor histologic response to initial chemotherapy have a poor overall prognosis." | ( Ford, HL; Jedlicka, P; McKinsey, E; Reaves, L; Robin, TP; Smith, A, 2012) |
| "Ewing's sarcoma is a malignancy characterized by a specific 11:22 chromosomal translocation which generates a novel EWS-FLI1 fusion protein functioning as an aberrant transcription factor." | ( Gopal, G; Jully, B; Rajkumar, T; Sabitha, K; Vijayalakshmi, R, 2012) |
| "Ewing's sarcoma is a rare, mostly pediatric bone cancer that presents a chromosome abnormality called EWS/Fli-1, responsible for the development of the tumor." | ( Bernard, G; Bertrand, JR; de Martimprey, H; Malvy, C; Ponchel, G; Ramon, AL; Vauthier, C, 2013) |
| "Ewing sarcoma is a primary bone tumor that rarely occurs in the hand." | ( Fernández-Hernández, O; Flores Corral, T; Ramos-Pascua, LR; Sánchez Herráez, S; Santos Sánchez, JÁ, 2013) |
| "Extraskeletal Ewing's sarcoma is a rare malignant soft tissue tumor, classified within the Ewing's Sarcoma Family Tumors." | ( Angelici, A; Brunotti, G; Manfredelli, S; Marcantonio, M; Pontone, S; Zitelli, A, 2013) |
| "Ewing sarcoma is characterized by multiple deregulated pathways that mediate cell survival and proliferation." | ( Ambati, SR; Chiosis, G; Kosugi, K; Lopes, EC; Meyers, PA; Mony, U; Moore, MA; Moreira, AL; Shah, SK; Taldone, T; Zehir, A, 2014) |
| "Ewing sarcoma is a transcription factor-mediated pediatric bone tumor caused by a chromosomal translocation of the EWSR1 gene and one of several genes in the ETS family of transcription factors, typically FLI1 or ERG." | ( Aiyer, RA; Buford, AS; Culotta, KS; Doolittle, DK; Lamhamedi-Cherradi, SE; Ludwig, JA; Maywald, RL; Menegaz, BA; O'Dorisio, JE; Ramamoorthy, V, 2015) |
| "Ewing sarcoma is an aggressive bone and soft tissue tumor in children and adolescents, with treatment remaining a clinical challenge." | ( Alexe, G; Chen, L; Cowley, G; Crompton, B; Kennedy, AL; Kim, S; Parasuraman, S; Stegmaier, K; Tsherniak, A; Vallurupalli, M; Vazquez, F; Weir, BA, 2015) |
| "Ewing's sarcoma is a malignant pediatric bone tumor with a poor prognosis for patients with metastatic or recurrent disease." | ( Barthorpe, S; Benes, CH; Garnett, MJ; Gill, SJ; Jackson, SP; Kogera, FA; McDermott, U; Mironenko, T; Pshenichnaya, I; Richardson, L; Stratton, MR; Travers, J, 2015) |
| "Ewing sarcoma is an aggressive bone and soft-tissue tumor that is characterized by overexpression of polycomb proteins." | ( Borinstein, SC; Hawkins, AG; Laird, PW; Lawlor, ER; Martens, JR; Punj, V; Ryland, KE; Weisenberger, DJ, 2016) |
| "Ewing Sarcoma is a rare bone and soft tissue malignancy affecting children and young adults." | ( Amiaud, J; Baud'huin, M; Bradner, JE; Heymann, D; Jacques, C; Lamoureux, F; Ory, B; Quillard, T; Rédini, F; Rodriguez Calleja, L; Tirode, F, 2016) |
| "The incidence of Ewing sarcoma is lower in non-Caucasian populations, compared with Caucasian populations, for unknown reasons." | ( Aoki, Y; Araki, N; Hamada, K; Imura, Y; Joyama, S; Kakunaga, S; Naka, N; Obata, H; Takenaka, S; Ueda, T; Yoshikawa, H, 2016) |
| "Ewing sarcoma is driven by characteristic chromosomal translocations between the EWSR1 gene with genes encoding ETS family transcription factors (EWS-ETS), most commonly FLI1." | ( Borinstein, SC; Chiang, C; Fleming, JT; Guo, Y; Loganathan, SN; Ma, Y; Tang, N; Wang, J, 2016) |
| "Ewing's sarcoma is a rare and aggressive malignancy." | ( Bouvet, M; Chishima, T; DeLong, JC; Dry, SM; Eckardt, MA; Eilber, FC; Endo, I; Federman, N; Hiroshima, Y; Hoffman, RM; Igarashi, K; James, AW; Kawaguchi, K; Kiyuna, T; Li, Y; Matsuyama, R; Murakami, T; Russell, T; Singh, AS; Tanaka, K; Yanagawa, J; Zhang, Y, 2016) |
| "Ewing sarcoma is the second most common bone tumor, occurring mainly in children and young adults." | ( Brons, P; Flucke, U; Salet, MC; Schreuder, B; Vogels, R, 2016) |
| "Ewing sarcoma is a highly aggressive bone and soft tissue cancer that is caused by the EWS-FLI1 fusion protein." | ( Gordon, DJ; Goss, KL, 2016) |
| "Ewing sarcoma is emblematic of this need, as it depends on the continued activity of the EWS-FLI1 transcription factor to maintain the malignant phenotype." | ( Aviles, PM; Boguslawski, EA; Bowman, MJ; D'Incalci, M; Easton, MK; Galmarini, CM; Grohar, PJ; Guillen Navarro, MJ; Harlow, ML; Hostetter, G; Johnson, BK; Kitchen-Goosen, SM; Madaj, ZB; Maloney, N; Roland, J; Turner, L; Winn, ME, 2016) |
| "Patients with Ewing sarcoma are subject to various diagnostic procedures that incur exposure to ionising radiation." | ( Aukland, SM; Biermann, M; Boye, K; Fasmer, KE; Johnsen, B; Rosendahl, K; Trovik, C, 2017) |
| "Ewing sarcoma is a highly resistant disease with a <10% chance of survival at 5 years after failure of frontline chemotherapy." | ( Adams, N; Barve, M; Ghisoli, M; Gutierrez, B; Manley, M; Manning, L; Mennel, R; Murphy, KM; Nemunaitis, J; Oliai, BR; Rangadass, P; Rao, D; Rutledge, M; Senzer, N; Stephens, PJ; Walker, A; Wallraven, G; Wang, Z, 2017) |
| "Ewing's sarcoma is a recalcitrant tumor greatly in need of more effective therapy." | ( Chishima, T; Dry, SM; Eckardt, MA; Eilber, FC; Endo, I; Hiroshima, Y; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Matsuyama, R; Miyake, K; Momiyama, M; Murakami, T; Singh, AS, 2018) |
| "Ewing sarcomas are rare mesenchymal-derived bone and soft tissue tumors in children." | ( Appert, A; Beauchamp, RD; Chung, DH; Lindsley, CW; Padmanabhan, C; Qiao, J; Rellinger, EJ; Waterson, AG, 2017) |
| "Ewing sarcoma is a locally aggressive, highly malignant tumor most commonly seen in the skeletal system." | ( Haas, JA; Morrison, CS; Rice, D, 2019) |
| "Ewing sarcoma is an aggressive solid tumor malignancy of childhood." | ( Alexe, G; Berman, JN; Boxer, MB; Conway Saur, A; Crompton, BD; Davis, MI; Guha, R; Hall, MD; Hughes, E; Hwang, EE; Kung, A; Lemieux, ME; McKnight, C; Melong, N; O'Neill, AF; Shen, M; Stegmaier, K; Veinotte, CJ; Wang, A; Wang, S; Wuerthele, K; Xu, X, 2019) |
| "Extraskeletal Ewing sarcoma is rare." | ( Cui, Y; Dong, A; Wang, Y; Zhang, J, 2019) |
| "Ewing sarcoma is a bone tumor most commonly diagnosed in adolescents and young adults." | ( Bailey, KM; Hawkins, AG; Julian, CM; Konzen, S; Lawlor, ER; Treichel, S, 2019) |
| "Extraosseous Ewing sarcoma is a rare, poorly differentiated round-cell tumour that is part of the Ewing sarcoma family of tumours." | ( Khalifeh, I; Maroun, CA; Moukarbel, RV; Tfayli, A, 2019) |
| "Ewing sarcoma is an aggressive tumor of bone and soft tissue, mainly affecting adolescents and young adults." | ( Palombo, R; Paronetto, MP; Verdile, V, 2020) |
| "Ewing sarcoma is a bone and soft tissue tumor predominantly affecting adolescents and young adults." | ( Balaguer-Lluna, L; Burgueño, V; Carcaboso, AM; Castañeda, A; Castillo-Ecija, H; Cuadrado-Vilanova, M; de Alava, E; Garcia-Dominguez, DJ; Gomez-Gonzalez, S; Hontecillas-Prieto, L; Lavarino, C; Monterrubio, C; Mora, J; Olaciregui, NG; Paco, S; Pascual-Pasto, G; Perez-Jaume, S; Resa-Pares, C; Restrepo-Perdomo, C; Roldan, M; Santa-Maria, V; Suñol, M; Vila-Ubach, M, 2020) |
| "Ewing sarcoma is a poorly differentiated and aggressive tumor mostly seen in the children and adolescents." | ( Bas, O; Ceylan, F; Dizdar, O; Guven, DC; Kilickap, S; Yildirim, HC, 2021) |
| "Ewing sarcoma is the second most common primary malignant bone tumor that usually affects diaphysis of long bones during the second decade of life." | ( Agarwal, R; Gupta, N; Khare, A, 2021) |
| "Ewing sarcomas are driven by EWS-ETS fusions, most commonly EWS-FLI1, which promotes widespread metabolic reprogramming, including activation of serine biosynthesis." | ( Apfelbaum, AA; Bradin, J; Chen, D; Cierpicki, T; Garcia, AX; Grembecka, J; Haarer, E; Hawkins, AG; Jiménez, JA; Kumar, A; Lawlor, ER; Lyssiotis, CA; Nwosu, ZC; Purohit, T; Ruiz, RO; Svoboda, LK, 2021) |
| "Ewing's sarcoma is one of the primary pediatric malignancies in which PET/CT with 18F-labeled fluorodeoxyglucose (18F-FDG) has demonstrated greater sensitivity in the evaluation of bone metastases compared to scintigraphy, as well as in the evaluation of treatment response." | ( Adlerstein L, I; Barahona Z, D; Faure R, MI, 2020) |
| "Subcutaneous Ewing sarcoma is very rare." | ( Gong, W; Liao, T; Liu, Y; Wu, J; Zhang, C, 2021) |
| "Ewing sarcoma is the second most common primary bone tumor in children." | ( Binkovitz, LA; Broski, SM; Guo, RR; Huls, SJ, 2022) |
| "Ewing sarcoma is one of the most frequent soft-tissue tumors in pediatric patients." | ( Bach, E; Brückner, M; Franke, GN; Heyn, S; Jentzsch, M; Leiblein, S; Niederwieser, D; Pfannes, R; Platzbecker, U; Pönisch, W; Remane, Y; Rieprecht, S; Schwind, S; Vucinic, V, 2022) |
| "Ewing sarcoma is an aggressive childhood cancer for which treatment options remain limited and toxic." | ( Bakin, AV; Gupta, A; Martin, JC; Ohm, JE; Sims, JR, 2022) |
| "Prostate Ewing sarcoma is rare." | ( Guo, YH; Yang, MF, 2022) |
| "Extraosseous Ewing's sarcoma is a rare tumor which is aggressive with poor prognosis; it can occur anywhere in the body, but scantily in the pancreas." | ( Chan, WT; Hou, JY; Jiang, CB; Lee, HC; Liu, HC; Liu, YC; Sheu, JC; Wu, PS; Yeh, TC; Yeung, CY, 2022) |
| "Extraosseous Ewing's sarcoma is a rare tumor which is aggressive with poor prognosis; it can occur anywhere in the body, but scantily in the pancreas." | ( Chan, WT; Hou, JY; Jiang, CB; Lee, HC; Liu, HC; Liu, YC; Sheu, JC; Wu, PS; Yeh, TC; Yeung, CY, 2022) |
| "Ewing sarcomas are aggressive pediatric tumors of bone and soft tissues driven by in frame chromosomal translocations that yield fusion proteins guiding the oncogenic program." | ( Alberdi, A; Capone, A; Chiurchiù, V; Matteocci, A; Palombo, R; Paronetto, MP; Passacantilli, I; Terracciano, F; Tournier, S; Volpe, E, 2023) |
| "Ewing's sarcoma is a highly malignant childhood tumour whose outcome has hardly changed over the past two decades despite numerous attempts at chemotherapy intensification." | ( Beck, JF; Becker, S; Henao-Restrepo, JA; Proquitté, H; Sonnemann, J; Sturm, MJ, 2023) |
| Excerpt | Reference |
|---|
| "Seventy-six patients with localized Ewing's sarcoma who received primary treatment at M." | ( Chan, RC; Johnston, DA; Lindberg, RD; Murray, JA; Samuels, ML; Sutow, WW, 1979) |
| "Local control of Ewing's sarcoma may relate to increasing doses of radiation, especially when intensive chemotherapy is administered also." | ( Chabora, BM; Rosen, G; Tefft, M, 1977) |
| "Of the 20 children with primary Ewing's sarcoma treated with T-2 "adjuvant" chemotherapy, 15 had no evidence of recurrent disease for from 31+-82+ months (median 46+ months) from the start of treatment." | ( Caparros, B; Huvos, AG; Marcove, RC; McCormick, B; Mosende, C; Rosen, G, 1978) |
| "An autopsy study of 26 cases of Ewing's sarcoma treated with radiation to the primary site plus adjuvant chemotherapy has shown metastatic tumor in 23 cases." | ( Pomeroy, TC; Rabson, AS; Telles, NC, 1978) |
| "A patient with Ewing's sarcoma of the left scapula received prophylactic radiotherapy to the left lung following wide excision of the tumor." | ( Keinan, Z; Mintz, U; Wainrach, B, 1976) |
| "Since 1964, 66 consecutive patients with Ewing's sarcoma have been treated at the National Cancer Institute with local irradiation of the primary site combined with adjuvant regimens of progressively more intensive systemic chemotherapy." | ( Johnson, RE; Pomeroy, TC, 1975) |
| "The diagnosis and treatment of Ewing's sarcoma are reviewed." | ( Fitzer, PM; Steffey, WR, 1976) |
| "Twelve patients with localized Ewing's sarcoma were treated between 1980-1990 at the Istanbul School of Medicine, Department of Pediatric Oncology-Hematology, Oncology Research and Treatment Center and Our Children Leukemia Foundation." | ( Gedikoğlu, G; Zülfikar, B, 1992) |
| "Current multimodality treatment for Ewing's sarcoma consists of combination chemotherapy with doxorubicin, vincristine, and cyclophosphamide (or ifosfamide in current trials) prior to and concurrent with radiation therapy for the involved bone." | ( Antman, KH, 1992) |
| "In the treatment of osteosarcoma and Ewing's sarcoma, ifosfamide has been identified as an effective drug." | ( Dirix, LY; Van Oosterom, AT, 1990) |
| "Between 1975 and 1985, 16 patients with Ewing's sarcoma were treated in the Adult Sarcoma Clinic at the Dana-Farber Cancer Institute." | ( Antman, KH; Ryan, LM; Siegel, RD, 1988) |
| "Records of 154 patients with Ewing's sarcoma treated at the National Cancer Institute were reviewed to assess the incidence and risk of developing isolated central nervous system (CNS) Ewing's sarcoma." | ( Glaubiger, D; Makuch, R; Trigg, ME, 1985) |
| "Eleven patients with untreated primary Ewing sarcoma were studied with intravenously administered 13N-labeled L-glutamate." | ( Benua, RS; Gelbard, AS; Laughlin, JS; Reiman, RE; Rosen, G, 1982) |
| "Since 1978, four patients with Ewing's sarcoma have been on a treatment-regimen based on the T-6 and T-2 Protocols according to Rosen." | ( Horrig, C; Ribeiro-Ayeh, J; Walther, A, 1982) |
| "Two patients with Ewing's sarcoma relapsed (1 patient with both local and distant failure) at 26 and 58 months and were again rendered disease-free with surgery, total body irradiation and further chemotherapy." | ( Fraass, BA; Kinsella, TJ; Loeffler, JS; Tepper, J, 1983) |
| "To assess the value in Ewing's sarcoma of a new multiagent therapy (vincristine, cyclophosphamide, Adriamycin, (doxorubicin) procarbazine), 30 children with a localized tumor (eight distal, nine proximal, 13 central lesions) treated at the Institut Gustave-Roussy between 1973 and 1976 (E3), were pair-matched by site of primary with 30 control patients treated without intensive chemotherapy between 1967 and 1972 (E1) at the same institution, both groups having the same local radiotherapy." | ( Blache, R; Henry-Amar, M; Patte, C; Sarrazin, D; Schweisguth, O; Zucker, JM, 1983) |
| "Twenty-seven patients with biopsy proven Ewing's sarcoma were randomised to receive one of two adjuvant chemotherapy regimens for two years." | ( Campbell, AM; Ekert, H; Waters, KD, 1983) |
| "Neuroblastoma and Ewing's sarcoma are examples of pediatric cancers in which disseminated disease is often present at diagnosis or develops later in spite of combination therapy." | ( Coccia, P; Graham-Pole, J; Gross, S; Herzig, RH; Lazarus, HM; Strandjord, S; Weiner, R, 1984) |
| "Twenty-four consecutive patients with Ewing's sarcoma were treated in a protocol designed to deliver induction chemotherapy with postinduction surgical-pathologic evaluation of the primary tumor site." | ( Coburn, T; Hayes, FA; Hustu, HO; Kumar, M; Thompson, EI; Webber, B, 1983) |
| "Eleven patients with extraskeletal Ewing's sarcoma (EES) were treated with combined modality therapy at the National Cancer Institute." | ( Costa, J; Dickman, PS; Glaubiger, D; Kinsella, TJ; Tepper, JE; Triche, TJ, 1983) |
| "Twenty-nine patients with Ewing's sarcoma of the lower extremity who survived for two or more years following therapy (5000 rad locally and systemic chemotherapy) were studied to assess functional status of the affected leg." | ( Binder, H; Bull, C; Cramer, H; Gerber, NL; Glaubiger, DL; Jentzsch, K; Kessler, RM; Pomeroy, TC, 1981) |
| "We treat Ewing's sarcoma by Rosen's T-11 protocol (CYT." | ( Tomita, K; Tsubota, S; Tsuchiya, H, 1993) |
| "Seventeen patients with Ewing's sarcoma were divided into 3 groups according to treatment." | ( Hamada, M; Inoue, H; Nakagawa, Y; Ozaki, T; Sugihara, S; Taguchi, K, 1993) |
| "Therapy of Ewing's sarcoma requires a qualified clinical, radiological, and pathohistological diagnosis and, in particular, an optimal therapy by an experienced team of oncological specialists." | ( Dunst, J; Sauer, R, 1993) |
| "In nine patients with osteogenic or Ewing sarcoma, we evaluated the use of magnetic resonance angiography (MRA) to assess neovascularity non-invasively in vivo and to monitor response to chemotherapy." | ( Genant, HK; Gooding, CA; Johnston, JO; Lang, P; Matthay, KK; Rosenau, W; Vahlensieck, M, 1996) |
| "Thirty-seven patients with Ewing sarcoma were treated in the First National Chilean Trial for Ewing's Sarcoma (1986-1991), which comprised the St." | ( Luo, X; Messen, S; Rayo, Y; Rojas, J; Salgado, C; Tordecilla, J; Villarroel, M; Zolezzi, P, 1997) |
| "Eighteen patients with poor risk Ewing's sarcoma (including 11 patients with metastatic disease at presentation) received consolidation therapy of busulphan and melphalan with autologous stem cell rescue." | ( Ashley, S; Atra, A; Calvagna, V; Pinkerton, CR; Shankar, AG; Shepherd, V; Souhami, RL; Whelan, JS, 1997) |
| "Twenty-four high-risk Ewing's sarcoma patients were treatedf on an intensive combined modality protocol including low-dose fractionated total body irradiation (TBI) and autologous bone marrow infusion (ABMI)." | ( Diesseroth, A; Glatstein, E; Glaubiger, D; Kinsella, TJ; Makuch, R; Pizzo, P; Waller, B, 1983) |
| "As most failures in Ewing's sarcoma are systemic, improved EFS requires more effective systemic chemotherapy." | ( Donaldson, SS; Gilula, L; Glicksman, A; Laurie, F; Link, MP; Manning, J; Neff, J; Reinus, W; Shuster, JJ; Thompson, E; Torrey, M, 1998) |
| "The risk of leukemia after treatment for Ewing's sarcoma is probably in the range of 2%." | ( Ahrens, S; Dunst, J; Harms, D; Jürgens, H; Paulussen, M; Rübe, C; Winkelmann, W; Zoubek, A, 1998) |
| "Extraskeletal Ewing's sarcoma is rare, and very few data are available addressing optimal surgical and oncologic treatment modalities." | ( Ahmad, R; Davis, M; Mayol, BR; Rougraff, BT, 1999) |
| "A 10-year old girl with Ewing's sarcoma in the right femur was treated with Ukrain and hyperthermia." | ( Aschhoff, B, 1998) |
| "Data on 359 patients with nonmetastatic Ewing's sarcoma of bone treated at a single institution between January 1979 and April 1995 were retrospectively considered." | ( Bacchini, P; Bacci, G; Bertoni, F; Donati, D; Ferrari, S; Forni, C; Longhi, A; Manfrini, M; Picci, P; Rimondini, S, 2000) |
| "We describe a 16-year-old girl with a Ewing sarcoma who was given post-operative treatment with HDI (15 mg/m(2) infused over 5 days)." | ( Frisk, P; Stålberg, E; Strömberg, B, 2001) |
| "Therapeutic trials for localized Ewing's sarcoma should be based on the histological response to chemotherapy or on the tumour volume according to the modality used for local therapy." | ( Babin-Boillettot, A; Bui, BN; Carrie, C; Deley, MC; Gentet, JC; Mechinaud, F; Michon, J; Oberlin, O; Philip, T; Schmitt, C; Terrier, P, 2001) |
| "All patients with Ewing sarcoma or rhabdomyosarcoma received additional concurrent chemotherapy." | ( Ballo, MT; Benjamin, RS; Burgess, MA; Cormier, JN; Feig, BW; Herzog, CE; Hunt, KK; Patel, SR; Pisters, PW; Raney, RB; Zagars, GK, 2001) |
| "Six hundred ninety Ewing tumor patients were treated between 1992 and 1999 with local therapy and vincristine." | ( Ahrens, S; Aulitzky, WE; Dunst, J; Fölsch, UR; Göbel, U; Harms, D; Hense, HW; Henze, G; Jürgens, H; Kremens, B; Lehnert, M; Niemeyer, C; Paulussen, M; Reiter, A; Taeger, D; Voûte, PA; Wagner, A; Zoubek, A, 2001) |
| "Since 1985, 54 with localized Ewing's sarcoma of bone were treated at the Onco-Orthopedics Clinic of the Sofia University Hospital (Sofia, Bulgaria)." | ( Mihova, A; Mumdjiev, I; Sokolov, T; Stoianova, A, 2001) |
| "Although the overall results of treatment of Ewing's tumors have improved, patients with high-risk factors, including metastatic disease at diagnosis, bulky primary tumors, axial sites, and age >15 years, continue to have poor prognoses." | ( Iwamoto, Y; Matsuda, S; Matsunobu, T; Sakamoto, A; Tanaka, K, 2002) |
| "We report a case of Ewing's sarcoma of the mandible and describe its clinicopathologic features and the treatment of this disease." | ( Alcalde, JM; Espinosa, JM; García-Tapia, R; Quesada, JL, 2003) |
| "A 17-year-old woman with Ewing sarcoma was treated with a combination of doxorubicin (Adriamycin) and ifosfamide during the 25th to 30th week of gestation, and the baby was delivered at the 32nd week." | ( Hirayama, M; Ishida, A; Nakajima, W; Ogawa, M; Okada, K; Takahashi, M; Takahashi, S; Washino, N, 2004) |
| "Here we report a patient treated for Ewing sarcoma with multiple pulmonary and osseous metastases who repeatedly developed a supraventricular tachyarrhythmia following administration of ifosfamide as part of a polychemotherapy regimen." | ( Kramm, CM; Lawrenz, W; Müller, L; Schmidt, KG; Wessalowski, R, 2004) |
| "The prognosis of patients with axial Ewing's sarcoma is dismal despite an intensive, multimodality approach including multiagent, alternating chemotherapy, surgery and/or radiotherapy." | ( Argon, A; Basaran, M; Bavbek, SE; Camlica, H; Darendeliler, E; Dizdar, Y; Onat, H; Ozger, H; Sakar, B; Yaman, F, 2004) |
| "Because Ewing's sarcoma (EWS) is extremely rare in the hand and forearm, only limited data are available for planning treatment or predicting prognosis." | ( Ahrens, S; Bernd, L; Daecke, W; Ewerbeck, V; Juergens, H; Kotz, R; Martini, AK; Winkelmann, W, 2005) |
| "Furthermore, Ewing's sarcoma tumor growth was significantly delayed by 100 mg/kg herceptin treatment in our Ewing's sarcoma xenograft mouse model." | ( Guan, H; Jia, SF; Kleinerman, ES; Stewart, J; Zhou, Z, 2005) |
| "Patients with Ewing's sarcoma, resistant to conventional therapy and with recurrent disease did not benefit from megachemotherapy." | ( Choma, M; Chybicka, A; Drabko, K; Gorczynska, E; Kałwak, K; Kowalczyk, J; Toporski, J; Turkiewicz, D; Wojcik, B; Zaucha-Prazmo, A; Zawitkowska-Klaczynska, J, 2005) |
| "Forty patients with localized Ewing sarcoma (ES) were treated with primary site RT at one institution." | ( Mai, WY; Nguyen, TX; Paulino, AC; Teh, BS; Wen, BC, 2007) |
| "Patients < or = 30 years with Ewing sarcoma, primitive neuroectodermal tumor or primitive sarcoma of bone were randomly assigned to receive chemotherapy with doxorubicin, vincristine, cyclophosphamide, and dactinomycin, (VACA) or with these four drugs alternating with ifosfamide and etoposide (VACA-IE)." | ( Bernstein, M; Chen, Z; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, M; Laurie, F; Miser, JS; Tarbell, NJ; Yock, TI, 2006) |
| "From 1979 to 2002, 27 patients with Ewing's sarcoma (20) or PNET (7) were treated." | ( Boven, E; Meijer, OW; Smorenburg, CH; van Groeningen, CJ; Visser, M, 2007) |
| "Advances in the treatment of Ewing sarcoma family of tumors (ESFT) are the result of improvements in systemic and local therapies." | ( Billups, CA; Krasin, MJ; Liu, T; Navid, F; Rao, BN; Rodríguez-Galindo, C, 2008) |
| "Neuroblastoma (NB) and Ewing sarcoma (ES) are neuroectodermal tumors typical of pediatric age that, despite aggressive treatment, still present a poor prognosis when in advanced stages." | ( Cordero di Montezemolo, L; Crescenzio, N; Doria, A; Fandi, A; Foglia, L; Timeus, F, 2008) |
| "The improvement of Ewing sarcoma (EWS) therapy is currently linked to the discovery of strategies to select patients with poor and good prognosis and of modified treatment regimens." | ( Caccuri, AM; Cantiani, L; Castellani, G; Francesconi, M; Knuutila, S; Manara, MC; Mercuri, M; Nardi, F; Picci, P; Remondini, D; Scotlandi, K; Serra, M, 2009) |
| "Cutaneous Ewing's sarcoma raises concerns about diagnosis and treatment." | ( Delaplace, M; Goré, C; Machet, L; Mélard, P; Perrinaud, A; Vergier, B, 2011) |
| "Most importantly, knockdown of EYA3 in Ewing sarcoma cells leads to sensitization to DNA-damaging chemotherapeutics used in the treatment of Ewing sarcoma, and as expected, after chemotherapeutic treatment, EYA3 knockdown cells repair DNA damage less effectively than their control counterparts." | ( Ford, HL; Jedlicka, P; McKinsey, E; Reaves, L; Robin, TP; Smith, A, 2012) |
| "Mice implanted with Ewing's sarcoma tumours received the following treatments: saline, ifosfamide, ifosfamide + NAC concurrently, pre-treatment with NAC + ifosfamide, or NAC alone." | ( Figueredo, R; Hanly, L; Koren, G; Koropatnick, J; Rieder, MJ, 2012) |
| "Treatment for unresectable Ewing's sarcoma family of tumors (ESFT) is a formidable challenge because of its high tendency for local and distant failure." | ( Hagiwara, Y; Imai, R; Ishii, T; Iwata, S; Kamada, T; Kumagai, K; Tatezaki, S; Yonemoto, T, 2013) |
| "A 9-year-old girl with Ewing sarcoma had one ovary excised and cryopreserved prior to chemo- and radiotherapy." | ( Andersen, CY; Birkebæk, NH; Clausen, N; Ernst, E; Kjærsgaard, M, 2013) |
| "For localized Ewing sarcoma, chemotherapy administered every 2 weeks is more effective than chemotherapy administered every 3 weeks, with no increase in toxicity." | ( Dickman, PS; Dormans, JP; Grier, HE; Healey, JH; Krailo, MD; Marcus, K; Pawel, BR; Sailer, S; Weiss, AR; West, DC; Womer, RB, 2012) |
| "The current standard treatment of Ewing's sarcoma is chemotherapy followed by surgery, making an immediate cranial reconstruction in a one-step surgical procedure possible." | ( Castle, M; Marquez, J; Rivero, M, 2013) |
| "Disseminated Ewing sarcoma remains a fatal disease despite advanced multimodal treatment regimens." | ( Ahlmann, M; Altvater, B; Chen, C; Dirksen, U; Juergens, H; Kailayangiri, S; Mueller, SK; Rossig, C, 2013) |
| "Novel treatment strategies in Ewing sarcoma include targeted cellular therapies." | ( Altvater, B; Beck, L; Dierkes, C; Faber, C; Hotfilder, M; Kailayangiri, S; Koch, R; Kooijman, H; Liebsch, L; Nagelmann, N; Ring, J; Rossig, C; Vieth, V, 2013) |
| "The poor prognosis of Ewing's sarcoma (EWS), together with its high lethal recurrence rate and the side‑effects of current treatments, call for novel targeted therapies with greater curative effectiveness and substantially reduced side‑effects." | ( Mateo-Lozano, S; Notario, V; Rahman, M; Sengupta, A; Tirado, OM, 2013) |
| "Standard-risk Ewing sarcomas were localized tumors with either a good histologic response to chemotherapy (< 10% cells) or small tumors (< 200 mL) resected at diagnosis or receiving radiotherapy alone as local treatment." | ( Brennan, B; Craft, A; Dirksen, U; Hjorth, L; Judson, I; Juergens, H; Ladenstein, R; Le Deley, MC; Le Teuff, G; Lewis, I; Marec-Bérard, P; Michon, J; Oberlin, O; Paulussen, M; Ranft, A; van den Berg, H; Wheatley, K; Whelan, J, 2014) |
| "PTEN status in Ewing sarcoma affects cellular responses to IGFI and mTOR-directed therapy, thus justifying its consideration as a biomarker in future clinical trials." | ( Davis, IJ; Gomez, NC; Kaiser-Rogers, K; McFadden, AW; Moats-Staats, BM; Patel, M; Rojas, A; Sapp, T; Simon, JM; Smith, SV; Wu, S, 2014) |
| "Patients with Ewing sarcoma family of tumors (ESFT) who are resistant even to salvage chemotherapy, have dismal prognoses and few therapeutic options." | ( Joo, J; Kwon, MM; Lim, KY; Park, BK; Park, HJ; Park, SY; Yoon, JH, 2014) |
| "Patients with Ewing sarcoma (EWS) who develop refractory or relapsed disease have limited treatment options." | ( Benson, C; Blay, JY; Dirksen, U; Gelderblom, H; Judson, I; Juergens, H; Placzke, J; Rasper, M; Rutkowski, P; van den Berg, H; van Maldegem, AM, 2015) |
| "Data on the Ewing sarcoma family of tumors (ESFT) of the head and neck region with uniform chemotherapy protocols are minimal." | ( Bakhshi, S; Biswas, B; Mohanti, BK; Thakar, A; Vishnubhatla, S, 2015) |
| "Data on patients with localized Ewing sarcoma family of tumors (ESFT) who have received a uniform chemotherapy protocol are minimal." | ( Agarwala, S; Bakhshi, S; Biswas, B; Deo, SV; Khan, SA; Mohanti, BK; Rastogi, S; Sharma, MC; Shukla, NK; Vishnubhatla, S, 2015) |
| "Metastatic Ewing Sarcoma carries a poor prognosis, and novel therapeutics to prevent and treat metastatic disease are greatly needed." | ( Al-Abed, Y; Behr, CA; Edelman, MC; Glick, RD; Hesketh, AJ; Maloney, C; Soffer, SZ; Steinberg, BM; Symons, M, 2015) |
| "Here we demonstrate that treating Ewing Sarcoma cells with JQ1(+), a BET bromodomain inhibitor, represses directly EWS-Fli1 transcription as well as its transcriptional program." | ( Amiaud, J; Baud'huin, M; Bradner, JE; Heymann, D; Jacques, C; Lamoureux, F; Ory, B; Quillard, T; Rédini, F; Rodriguez Calleja, L; Tirode, F, 2016) |
| "Twenty Ewing sarcoma patients diagnosed in Norway in 2005-2012 met the inclusion criteria (age <30 years, operable disease, uncomplicated chemotherapy and surgery, no metastasis or residual disease within a year of diagnosis)." | ( Aukland, SM; Biermann, M; Boye, K; Fasmer, KE; Johnsen, B; Rosendahl, K; Trovik, C, 2017) |
| "The long-term overall survival of Ewing sarcoma (EWS) patients remains poor; less than 30% of patients with metastatic or recurrent disease survive despite aggressive combinations of chemotherapy, radiation and surgery." | ( Alturkmani, H; Baltezor, M; Butte, AJ; Chen, B; Flynn, CA; Godwin, AK; Hyter, S; Ma, Y; Neville, KA; Pessetto, ZY; Rosenthal, HG; Weir, SJ, 2017) |
| "A tumor from a patient with soft-tissue Ewing's sarcoma, who failed doxorubicin (DOX) therapy, was previously implanted in nude mice to establish a patient-derived orthotopic xenograft (PDOX) model." | ( Bouvet, M; Chishima, T; DeLong, JC; Dry, SM; Eilber, FC; Endo, I; Hiroshima, Y; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Lwin, TM; Miyake, K; Murakami, T; Nelson, SD; Singh, AS; Tanaka, K; Zhang, Y; Zhao, M, 2017) |
| "This is a case report of an Ewing sarcoma patient with metastatic disease recurrence <2 years after standard chemotherapy/radiation who achieved a durable and sustained complete response after 2 series of treatments with Vigil (GMCSF/bi-shRNA furin DNA autologous tumor immunotherapy) serially manufactured from first and second recurrences with ELISPOT assay correlation." | ( Adams, N; Barve, M; Ghisoli, M; Gutierrez, B; Manley, M; Manning, L; Mennel, R; Murphy, KM; Nemunaitis, J; Oliai, BR; Rangadass, P; Rao, D; Rutledge, M; Senzer, N; Stephens, PJ; Walker, A; Wallraven, G; Wang, Z, 2017) |
| "In patients with Ewing sarcoma and some distinct subgroups of soft tissue sarcoma (STS), a quantitatively sufficient autologous peripheral blood stem cell (PBSC) collection for stem cell support might facilitate treatment continuation, dose-intensification, and high-dose chemotherapy." | ( Bruckner, T; Cremer, M; Egerer, G; Heilig, C; Kriegsmann, K; Kriegsmann, M; Müller-Tidow, C; Novotny, P; Wuchter, P, 2017) |
| "Twenty-nine newly diagnosed Ewing sarcoma patients with pretreatment MRI (of whom 11 also underwent FDG-PET) were included." | ( Boellaard, R; Glaudemans, AWJM; Jutte, PC; Kasalak, Ö; Kwee, TC; Overbosch, J, 2018) |
| "For 13 patients with Ewing sarcoma, whole-body FDG PET-CT was assessed for site of primary disease, disease extent, and response to therapy." | ( Attinà, G; Giordano, A; Lanni, V; Librizzi, A; Mastrangelo, S; Maurizi, P; Riccardi, R; Ruggiero, A, 2018) |
| "The treatment of Ewing sarcoma has changed very little in the past two decades and novel treatment approaches are needed." | ( Gordon, DJ; Goss, KL; Koppenhafer, SL; Terry, WW, 2018) |
| "Children with Ewing sarcoma (ES) are subjected to an interval-compressed regimen with cycles of chemotherapy given every 2 weeks, which is nowadays considered to be the standard of care for individuals with such a case." | ( Alnassan, A; Elshahoubi, A; Sultan, I, 2019) |
| "Adult Ewing sarcoma (ES) is a rare disease, the optimal treatment model is unknown." | ( He, A; Hu, H; Huang, Y; Shen, Z; Sun, Y; Yao, Y; Zhang, J; Zhou, Y, 2019) |
| "Patients with Ewing sarcoma or osteosarcoma have a median overall survival of less than 12 months after diagnosis, and a standard treatment strategy has not yet been established." | ( Bellera, C; Bessede, A; Blay, JY; Bompas, E; Chevreau, C; Crombe, A; Duffaud, F; Entz-Werlé, N; Gaspar, N; Italiano, A; Kind, M; Lervat, C; Marec-Berard, P; Mathoulin-Pelissier, S; Mir, O; Pacquement, H; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Saada, E; Toulmonde, M; Wright, J, 2020) |
| "A 49-year-old male with Ewing sarcoma and bone, pleural, lung and mediastinal lymph node metastasis was treated with cabozantinib after four lines of previous systemic treatments." | ( Everaert, H; Lesfevre, P; Schallier, D, 2020) |
| "Herein, we represent a case of relapsed Ewing sarcoma treated with multiple lines of chemotherapy." | ( Bas, O; Ceylan, F; Dizdar, O; Guven, DC; Kilickap, S; Yildirim, HC, 2021) |
| "The treatment of Ewing sarcoma, an aggressive bone and soft tissue sarcoma, is associated with suboptimal outcomes and significant side-effects." | ( Gordon, DJ; Goss, KL; Koppenhafer, SL; Terry, WW; Waters, T, 2020) |
| "In the treatment of recurrent Ewing sarcoma, investigators should consider the use of a 10-day schedule for administration of irinotecan." | ( Meyers, PA; Slotkin, EK, 2023) |
| "Advances in the biology of Ewing sarcoma, which continues to be an important cause of mortality, have caused an increase in information in the literature related to the underlying molecular base of the disease and discussions of new treatment approaches." | ( Aliç, T; Hassa, E, 2022) |
| "Advances in the biology of Ewing sarcoma, which continues to be an important cause of mortality, have caused an increase in information in the literature related to the underlying molecular base of the disease and discussions of new treatment approaches." | ( Aliç, T; Hassa, E, 2022) |
| "Advances in the biology of Ewing sarcoma, which continues to be an important cause of mortality, have caused an increase in information in the literature related to the underlying molecular base of the disease and discussions of new treatment approaches." | ( Aliç, T; Hassa, E, 2022) |
| "Osteosarcoma (OS) and Ewing sarcoma (ES) are aggressive childhood bone cancers with stagnant survival statistics and limited treatment options." | ( Chhonker, YS; Feng, D; Ford, JB; Haney, SL; Holstein, SA; Murry, DJ; Smith, LM; Varney, ML; Williams, JT, 2023) |
| "Osteosarcoma (OS) and Ewing sarcoma (ES) are aggressive childhood bone cancers with stagnant survival statistics and limited treatment options." | ( Chhonker, YS; Feng, D; Ford, JB; Haney, SL; Holstein, SA; Murry, DJ; Smith, LM; Varney, ML; Williams, JT, 2023) |
| "Osteosarcoma (OS) and Ewing sarcoma (ES) are aggressive childhood bone cancers with stagnant survival statistics and limited treatment options." | ( Chhonker, YS; Feng, D; Ford, JB; Haney, SL; Holstein, SA; Murry, DJ; Smith, LM; Varney, ML; Williams, JT, 2023) |
| "Although Ewing's sarcoma (ES) is a rare, but very aggressive tumor disease affecting the musculoskeletal system, especially in children, it is very aggressive and difficult to treat." | ( Ekkernkamp, A; Haralambiev, L; Niethard, M; Nitsch, A; Qarqash, S; Reichert, JC; Römer, S; Schoon, J; Tzvetkov, MV; Wassilew, GI, 2023) |